新葡的京首頁-欢迎您

Company ProfileCompany Profile

H-DataNet（Beijing）Technology Co.,Ltd.（H-DataNet）was founded in November 2022,with three holding subsidiaries[Genelife（Beijing）Technology Co.Ltd.（Genelife），ZHIBAO（Beijing0Technology Co.,Ltd.（ZHIBAO），Remedial AI（Beijing）Technology Co.,Ltd（Remedial AI）]，H-DataNet focuses on the application of medical and healthcare big data and artificial intelligence technology to provide accurate and intelligent solutions for hospitals, the Health Commission, the Health Insurance Bureau and the Center for Disease Control and Prevention, realizing the linkage of healthcare, pharmaceuticals and healthcare insurance, so as to significantly improve the efficiency of the healthcare industry chain,and promote the sustainable and healthy development of the medical and healthcare industry.

Founded in August 2015, Genelife（Beijing）Technology Co.Ltd.（Genelife）is a leading healthcare big data and artificial intelligence innovator in China, a national high-tech enterprise and a Beijing specialized enterprise. In 2016, Genelife took the lead in launching the precision medicine big data platform products in China, undertook five national key research and development projects with famous medical institutions in China, and supported four top multi-center disciplinary alliances in China, which empowers and enhances the efficiency of many key links in the healthcare industry chain.

Founded in August 2015, Genelife（Beijing）Technology Co.Ltd.（Genelife）is a leading healthcare big data and artificial intelligence innovator in China,a national high-tech enterprise and a Beijing specialized enterprise.In 2016, Genelife(Beijing)Technology Co.Ltd.（Genelife）took the lead in launching the precision medicine big data platform products in China,undertook five national key research and development projects with famous medical institutions in China, and supported four top multi-center disciplinary alliances in China, which empowers and enhances the efficiency of many key links in the healthcare industry chain.

Founded in December 2023, Remedial AI（Beijing）Technology Co.,Ltd（Remedial AI）is a pharmaceutical science and technology innovation enterprise, which is committed to promoting the research and development of innovative medicines and target discovery with its self-developed Disease-Gene-Drug Knowledge Graph（"OPKG"）and pre-trained large model（"ONCOSAGE"）, target discovery and other areas of products and services. Our mission is to accelerate the process of drug development and production to help patients overcome diseases and improve their quality of life.

In April 2023, H-DataNet and Genelife completed strategic reorganization, and the group headquarters moved to the core area of China World Trade Center in Beijing. The core founding team members all graduated from Peking University, including former core technical backbones of BAT Internet companies, international pharmaceutical companies and former executives and technical backbones of well-known domestic IT companies, while internationally renowned biomedical big data scientists serve as the company's co-founders and scientific advisors. Consultant. H-DataNet Group has cooperated with 300 domestic medical service organizations（including over 30 domestic top 100 hospitals）, medical insurance organizations, and bio-pharmaceutical companies, and has accumulated experience in processing over 200 million people,billions of records, and hundreds of billions of data items, and owns more than a hundred items of intellectual property rights.

In April, H-DataNet and Genelife completed strategic reorganization and moved into the core area of China World Trade Center; in June, ZHIBAO was invested and set up as a holding subsidiary; in December, Remedial AI Participated in the compilation of the group standard"General Principles of Technical Specification for Blockchain-Based Healthcare Applications"in May, and won the 1st Strong Nation Digital Health Innovation and Application Competition on Healthcare Big.

There are 3 branches
Holding subsidiaries
Serving 30⁺
Fudan top 100+ hospitals
Get 100⁺items
Intellectual property
Have 500⁺billions
Data governance experience

VisionVision

Vision
Data Intelligence, Ecological Connectivity
MissionMission

Mission
Building Healthcare Data
new ecology of factors
Healthy AttitudeValues

Healthy Attitude
Win-Win, Passion, Innovation, Growth

Development historyDevelopment history

New Singularity2023-Present Growing2021-2022 Build Momentum2018-2020 Setting Sail2015-2017

New Singularity: 2023
In April, H-DataNet and Genelife completed strategic reorganization and moved into the core area of China World Trade Center; in June, ZHIBAO was invested and set up as a holding subsidiary; in December, Remedial AI was invested and set up as a holding subsidiary.; 2023
Participated in the compilation of the group standard”General Principles of Technical Specification for Blockchain-Based Healthcare Applications"in May, and won the 1st Strong Nation Digital Health Innovation and Application Competition on Healthcare Big Data in December, with 1 grand prize, 1 third prize and 2 awards.

Growing: 2021
Supported China's largest kidney disease cohort innovation research; in April, the company was honored as one of China's top 100 digital healthcare companies; in August, it was honored as one of the"Top 10 Most Competitive Enterprises of Medical and Healthcare Big Data Platforms"in the First Healthcare Information Interconnection Conference held by the National Healthcare Commission.; 2022
In January, we were honored as one of the first batch of"Specialized and New"enterprises in Beijing in 2022; in May, "Guangdong Province Intelligent Multi-point Trigger Disease Prevention and Control Early Warning System"was honored as one of the Top 10 Replicable Cases of National Digital Health,and was commended by the National Healthcare Commission.

Build Momentum: 2018
Selected as one of the"Top 100 Future Healthcare Companies of 2018"and was honored as one of the"Most Promising Enterprises of 2018"in the same year.; 2019
Awarded as one of the"Top 50 Medical Technology Innovative Enterprises in China"in 2019, based on the in-depth research and accumulation of innovative enterprises in the pharmaceutical vertical field in the past two years, and strict judgment of the competitiveness of enterprises in various segments.; 2020
Won the tender for the first intelligent multi-point triggered disease prevention and control early warning and prediction system in China; DRG/DIP platform went on line; supported Wuhan Municipal Health Insurance Bureau to win the"first place in the country"in the evaluation of DRG technology expert group of the National Health Insurance Bureau.

Setting Sail: 2015
The company was founded.Composed of a team of international first-class experts in various fields such as data science, artificial intelligence, clinical medicine and bioinformatics, with strong R&D strength and cross-border integration capabilities.; 2016
Took the lead in launching VitArk16, a precision medicine big data platform product in China, which empowers healthcare organizations, medical insurers,and biopharmaceutical organizations, and significantly improves the efficiency of many key links in the healthcare industry chain.; 2017
Since the company was founded, it has cooperated with many hospitals across China to deploy big data platform products.

Core TeamCore Team

Jincheng Liu Chairman of the Board

Mr.Liu Jincheng majored in International Law in the class of 84 at Wuhan University, and studied EMBA at Tsinghua University School of Economics and Management and Wudaokou Finance School. On January 21, 2010 and July 7, 2021, he led two high-tech enterprises, Beijing Hekang Frequency Conversion 300048 and Wuxi Jiangnan Yifan 301023, to successfully land on the GEM board of the Shenzhen Stock Exchange and acted as the chairman of the board, and he has built the legend of being a leading enterprise of a specific industry for many times.

Liyu Liu Vice Chairman

Master of Computer Science from Peking University, he has participated in the formulation of informatization standards of the National Health Planning Commission for many times, served as a project expert of the Digital Healthcare Engineering Research Center of the Ministry of Education,and vice president of the Artificial Intelligence Sub-committee of the Communications Industry Association of China, and held a number of social positions. He has led a team to assist Peking University People's Hospital to become the first hospital in China to pass HIMSS EMRAM Stage 7 certification.

Zhongbo Li Director

University of South Australia（MBA）, licensed pharmacist, angel investor. He has led a pharmaceutical sales team of 1,000 people to create brilliant results, led the team of Hekang Xinneng（300048）to break the international monopoly of ABB and Siemens, and created many domestic firsts; successfully participated in a number of domestic and international private equity and equity investment, and has rich experience in the management of listed companies and domestic / international capital operation.

Ruixia Liu Director / CFO

Mrs.Liu Ruixia is a senior accountant with a master's degree in finance from Renmin University of China. Mrs.Liu has worked in Chundu A（SZ.000885）, Hekang Xinneng（SZ.300048）and other listed companies, serving as financial controller, deputy general manager, secretary of the board of directors, leading the construction of the company's compliance and internal control system; carry out equity financing, the introduction of strategic investors, and participate in leading the entire IPO, and successfully listed.

Xin He Director

PhD in Immunobiology from Yale University. Dr. He is a founding partner of hyfunity investments, a former senior partner of CDH Investments, and the CEO of Specialty Pharma, a pharmaceutical company. His portfolio companies include CureVac,Zhenghai Biotechnology, Surgical Robotics,Mabpharm, and TechVision, and many other domestic and international biopharmaceutical innovators and publicly traded companies.

Bing Zhang Director

President of China Mutual Fund-Beijing New Power Jinke Investment Company under the Central Bank. He is the partner of SaiLin Capital, a subsidiary of the Shanghai government, which was founded under the guidance of the central bank. He has rich experience in industrial investment, M&A and restructuring, industrial fund, market value management, etc. He has provided strategic consulting and capital consulting services for a number of subordinate organizations of central enterprises, such as Hyosung Group, AVIC, SINOMACH, and China Unicom.

Wenle Huang Director

Mr.Huang Wenle, the founder of Shangke Electrical Appliances, is the chairman of Shanghai Shangke Electrical Appliances（Group）Co.,Ltd, the chairman of Shanghai Jiaotong University National University Science and Technology Park-Nanqiao Park, and the vice president of Shanghai Electrical Appliances Industry Association. He has been plowing into the electrical appliances industry for decades,and led the Jiao Tong University Science and Technology Park to be honored as the municipal science and technology business incubator base in Shanghai in 2015.

CONSULTANTSCONSULTANTS

Yu Shry Senior Advisor
Chair, Department of Biostatistics, Vanderbilt University, USA; Voting member of the US FDA Committee; Associate Editor-in-Chief, JAMA Oncology; Member of NIH / NCI Research Program Review Committee.
Zemin Zhang Fellow Senior Advisor
Researcher and Director, Center for Biomedical Frontier Innovation, Peking University; Researcher, Center for Future Genetic Diagnostics, Peking University; Changjiang Distinguished Professor under China's"Overseas High-level Talents"Program; Senior Researcher of Peking University-Tsinghua Joint Center for Life Sciences.
Tang Buzhou Senior Consultant
Authorized expert in natural language processing in Chinese medicine; Vice Chairman of YOCSEF Shenzhen, Chinese Computer Society; Deputy Director and Secretary of"Healthcare and Bioinformatics Processing"Specialized Committee of Chinese Information Society.

Yu Shry Senior Advisor

Chair, Department of Biostatistics, Vanderbilt University, USA; Voting member of the US FDA Committee; Associate Editor-in-Chief, JAMA Oncology; Member of NIH / NCI Research Program Review Committee.

Zemin Zhang Fellow Senior Advisor

Researcher and Director, Center for Biomedical Frontier Innovation, Peking University; Researcher, Center for Future Genetic Diagnostics, Peking University; Changjiang Distinguished Professor under China's"Overseas High-level Talents"Program; Senior Researcher of Peking University-Tsinghua Joint Center for Life Sciences.

Tang Buzhou Senior Consultant

Authorized expert in natural language processing in Chinese medicine; Vice Chairman of YOCSEF Shenzhen, Chinese Computer Society; Deputy Director and Secretary of"Healthcare and Bioinformatics Processing"Specialized Committee of Chinese Information Society.